Hims & Hers Health Inc (NYSE:HIMS) does about 13.65M shares in volume on a normal day but saw 49224544 shares change hands in the recent trading day. The company now has a market cap of 7.18B USD. Its current market price is $31.35, marking an increase of 23.77% compared to the previous close of $25.33. The 52 week high reached by this stock is $30.44 whilst the lowest price level in 52 weeks is $8.02. The script in recent trading has seen the stock touch a high of $28 and a low of $8.
Hims & Hers Health Inc (HIMS) has a 20-day trading average at $23.09 and the current price is 2.99% off the 52-week high compared with 290.90% distance from its 52-week low. The 50-day simple moving average of the closing price is $20.85 and its 200-day simple moving average is $17.53. If we look at the stock’s price movements over the week, volatility stands at 14.04%, which decreases to 12.16% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 66.48 to suggest the stock is neutral.
13 analysts observing the Hims & Hers Health Inc (HIMS) stock have set the 12-month price targets for the company’s shares at between $8 and $28. The consensus objective for the share price is $25.23, suggesting that the stock has a potential downside of -24.26% over the period. The median price target is -36.3% away from the current levels at $23.
FactSet Research has provided data showing that 13 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 7 analysts have rated it as a buy and 5 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is 35.77%, 50.36%, and 78.84% away from its SMA20, SMA50, and SMA200 respectively, with the HIMS price moving below the 50-day SMA on current market day. Hims & Hers Health Inc (HIMS) stock is up 49.36% over the week and 44.27% over the past month. Its price is 252.25% year-to-date and 281.39% over the past year.
Its 12-month price target is $23. To reach the target analysts have set, the stock logically needs to shrink -24.26 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $8, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $28.
Outstanding shares total 205.10M with insiders holding 11.39% of the shares and institutional holders owning 66.10% of the company’s common stock. The company has a return on investment of 22.52% and return on equity of 26.35%. The price to earnings ratio (P/E ratio) amounts to 72.52 while the forward price to earnings ratio is 35.32. The beta has a value of 1.13. Price to book ratio is 15.52 and price to sales ratio is 5.78.
